Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Alnylam Pharmaceuticals (ALNY)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for ALNY as compared to
Top Competitors
Biotechnology
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS
No data.
Revenue
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
98.3M
AVG
EBITDA
►
-41.2M
AVG
Net Income
►
-49.2M
AVG
Revenue Growth
►
9.2%
AVG
Operating Margin
►
-48.8%
AVG
Net Margin
►
-50%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
1.72
AVG
Current Ratio
►
2.26
AVG
Quick Ratio
►
2.26
AVG
Interest Coverage Ratio
►
-187
LOW
Book Value Per Share
►
4.35
Cash Per Share
►
2.35
Loading...
STOCK SUMMARY
Open
16.87
Day Range
16.25
-
16.86
52 Week Range
14.82
-
26.36
Volume
107K
Avg Volume (3 mo)
235K
Shares Outstanding
41.1M
Market Cap
700M
VALUATION
Price to Earnings (P/E)
►
-13.7
Price to Book (P/B)
►
3.71
AVG
Price to Sales (P/S)
►
6.87
AVG
Return on Assets (ROA)
►
-9.1%
AVG
Return on Equity (ROE)
►
-25.4%
AVG
EV/EBITDA
►
-18.8
Dividend Yield
0%
AVG
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
-0.8%
Net Insider Buying 6mo
-1.2%
Net Insider Buying 1yr
-0.8%
Held by insiders
22.7%
Held by institutions
47.7%
No Sales Breakout Data.